Literature DB >> 20159513

PET and PET/CT for pancreatic malignancies.

Dominique Delbeke1, William H Martin.   

Abstract

FDG PET imaging is useful for preoperative diagnosis of pancreatic carcinoma in patients with suspected pancreatic cancer in whom CT fails to identify a discrete tumor mass or in whom FNAs are nondiagnostic. FDG PET imaging is useful for M staging and restaging by detecting CT occult metastatic disease, allowing noncurative resection to be avoided in this group of patients. FDG PET can differentiate post-therapy changes from recurrence and holds promise for monitoring neoadjuvant chemoradiation therapy. The technique is less useful in periampullary carcinoma and marginally helpful in staging except for M staging. As with other malignancies, FDG PET is complementary to morphologic imaging with CT, therefore, integrated PET/CT imaging provides optimal images for interpretation and thus more optimal patient care.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20159513     DOI: 10.1016/j.soc.2009.11.005

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  8 in total

1.  Pilot study: Evaluation of dual-energy computed tomography measurement strategies for positron emission tomography correlation in pancreatic adenocarcinoma.

Authors:  Jorge Oldan; Miao He; Teresa Wu; Alvin C Silva; Jing Li; J Ross Mitchell; William M Pavlicek; Michael C Roarke; Amy K Hara
Journal:  J Digit Imaging       Date:  2014-12       Impact factor: 4.056

2.  Is intraoperative confirmation of malignancy during pancreaticoduodenectomy mandatory?

Authors:  Pramod Kumar Mishra; Sundeep Singh Saluja; Asit Arora; Raja Kalayarasan
Journal:  J Gastrointest Surg       Date:  2012-11-21       Impact factor: 3.452

3.  Absence of a Periampullary Mass on Cross-sectional Imaging Delays Diagnosis and Time to Pancreatoduodenectomy But Does Not Impair Outcome.

Authors:  Hideo Takahashi; Maitham A Moslim; Naftali Presser; Colin O'Rourke; Jane Wey; Sricharan Chalikonda; Matthew R Walsh; Gareth Morris-Stiff
Journal:  J Gastrointest Surg       Date:  2016-03-16       Impact factor: 3.452

4.  Treatment of borderline resectable pancreatic cancer.

Authors:  Amanda B Cooper; Ching-Wei D Tzeng; Matthew H G Katz
Journal:  Curr Treat Options Oncol       Date:  2013-09

5.  Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions.

Authors:  Paul F Laeseke; Ru Chen; R Brooke Jeffrey; Teresa A Brentnall; Jürgen K Willmann
Journal:  Radiology       Date:  2015-12       Impact factor: 11.105

6.  Sensitivity and specificity of FDG PET-CT scan in detecting lymph node metastasis in operable periampullary tumours in correlation with the final histopathology after curative surgery.

Authors:  Prithivi Raj; Lileswar Kaman; Rajinder Singh; Divya Dahyia; Anish Bhattacharya; Amanjit Bal
Journal:  Updates Surg       Date:  2013-03-16

7.  The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines.

Authors:  Scott W Malm; Neale T Hanke; Alexander Gill; Liliana Carbajal; Amanda F Baker
Journal:  J Exp Clin Cancer Res       Date:  2015-04-01

8.  FDG-PET/CT-based restaging may alter initial management decisions and clinical outcomes in patients with locally advanced pancreatic carcinoma planned to undergo chemoradiotherapy.

Authors:  Erkan Topkan; Cem Parlak; Ali Fuat Yapar
Journal:  Cancer Imaging       Date:  2013-10-04       Impact factor: 3.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.